UBS analyst AJ Rice lowered the firm’s price target on Acadia Healthcare (ACHC) to $24 from $28 and keeps a Buy rating on the shares. Acadia lowered its 2025 guidance due to a $50M liability reserve accrual expected in Q4, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Leerink downgrades Acadia Healthcare on ‘real risk’ of legal liabilities
- Acadia Healthcare price target lowered to $25 from $30 at KeyBanc
- BofA downgrades Acadia Healthcare to Underperform after another guidance cut
- Acadia Healthcare downgraded to Underperform from Neutral at BofA
- Acadia Healthcare downgraded to Market Perform from Outperform at Leerink